Evidence map›Paper›PMID 42455928›Full record

ArticleScience advances2026

Single-cell transcriptomic unveils tumor-mediated reprogramming of neutrophils and their unique vulnerability that inhibits metastasis.

William Putzbach, Maria P Zappia, Ahmed Magdy, Jing Li, Veronique Nogueira, Kevin Lou, Kevan M Shokat, Abul B M M K Islam, Maxim Frolov, Nissim Hay

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

William PutzbachDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0002-2669-6654
Maria P ZappiaDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0003-0449-5445
Ahmed MagdyDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0002-8100-2141
Jing LiDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.
Veronique NogueiraDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0003-3289-1760
Kevin LouDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0003-4939-4381
Kevan M ShokatDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-8590-7741
Abul B M M K IslamDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0002-7274-0855
Maxim FrolovDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0003-3953-3739
Nissim HayDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0002-6245-3000

Funding

PI3K/PTEN/Akt signaling and the genesis of cancerR01CA090764 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Nissim Hay · 2001 to 2026
$9.4M
Hexokinase 2 and cancer therapyR01CA258299 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HAY, NISSIM · 2021 to 2025
$2.7M
Hexokinase 2 in liver cancerR01CA206167 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HAY, NISSIM · 2016 to 2020
$2.1M
BLRD VA I01 BX005092BLRD VA IK6 BX004602NCI NIH HHS R01 CA090764NCI NIH HHS R01 CA206167NCI NIH HHS R01 CA258299
6 · The paper itself

Abstract

Neutrophils are protumorigenic and prometastatic in tumor-bearing mice. Comprehensive single-cell RNA sequencing analyses on various tissues of naïve and tumor-bearing MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen) mice unraveled a neutrophil reprogramming process and uncovered a strategy to selectively target reprogrammed neutrophils. Transcriptional reprogramming of neutrophils in tumor-bearing mice is initiated in the bone marrow (BM) by granulocyte colony-stimulating factor (G-CSF). Among the seven neutrophil clusters in the BM, the abundance of one cluster is markedly increased whereas another cluster is diminished in tumor-bearing mice. This reprogramming endures across tissue types including blood, tumor microenvironment, and the metastatic niche in the lungs. Thus, in all tissues tested, neutrophils derived from tumor-bearing mice are transcriptionally distinct from those derived from naïve mice. Among the genes that are markedly induced are members of the

Indexed as

Cellular ReprogrammingNeutrophilsTranscriptomeAnimalsFemaleGene Expression Regulation, NeoplasticGranulocyte Colony-Stimulating FactorMiceNeoplasm MetastasisSingle-Cell AnalysisSingle-Cell Gene Expression AnalysisTumor MicroenvironmentGranulocyte Colony-Stimulating Factor

Identifiers

PMID42455928
PMCPMC13371899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.